Search PubMed⌕ Search

Biomedical subjects

J F Dasta

Publications and source records attributed to J F Dasta.

At least 55 records · Page 3Linked to original sources

Physiologic implications of mechanical ventilation on pharmacokinetics.

Numerous factors present in the critically ill patient decrease drug clearance. The contribution of one factor, mechanical ventilation, to this decrease is largely unknown and unquantified. This article attempts to review the physiologic effects of mechanical ventilation and to propose theoretical changes in the pharmacokinetics of concomitantly administered drugs. Mechanical ventilation with or without positive end-expiratory pressure is a well-documented cause of decreases in cardiac output, hepatic and renal blood flow, glomerular filtration rate, and urine flow. The mean airway pressure delivered, the pathophysiologic state of the patient, and coexisting therapeutic interventions affect the degree of hemodynamic alteration. Theoretically, these hemodynamic changes can decrease the clearance of several drugs frequently administered to critically ill patients. Decreased hepatic blood flow decreases the clearance of nonrestrictively cleared drugs. The pharmacokinetics of drugs predominantly renally cleared, by either glomerular filtration or tubular secretion, are affected by a decrease in renal blood flow or glomerular filtration rate. Also, the clearance of agents for which tubular reabsorption is important may decrease because the reduction in urine flow resulting from mechanical ventilation allows increased time for drug reabsorption. Interventions that minimize the decrease in cardiac output and organ blood flow and, theoretically, the risk of the adverse drug reactions from decreased drug clearance include expansion of intravascular volume, administering positive inotropic agents, and decreasing mean airway pressure. Monitoring serum concentration of critical and toxic agents suspected to have altered clearance in patients receiving mechanical ventilation is recommended. We hope that our article will stimulate future research in this area to give clinicians guidelines for drug dosing in patients receiving mechanical ventilation.

Humans↗

Intraoperative complications in patients receiving amiodarone: characteristics and risk factors.

This article reviews amiodarone's adverse cardiovascular properties, concentrating on those in surgical patients, and evaluates several potential risk factors. Amiodarone has negative inotropic and chronotropic properties as well as peripheral vasodilating properties that may manifest as bradycardia, reduced cardiac output, and hypotension. These reactions are clinically important during surgery, because of resistance to pharmacologic resuscitation and an increased mortality rate. Potential risk factors include ventricular dysfunction, rapid infusion rate, hypocalcemia, cardiopulmonary bypass, general anesthesia, concurrent negative inotropic or chronotropic drugs, and an elevated serum amiodarone or desethylamiodarone concentration. The following measures may decrease the risk of intraoperative adverse reactions in amiodarone-treated patients. The serum calcium concentration should be at the physiologic level and the serum amiodarone and digoxin concentrations should be in the therapeutic range. Negative inotropic and chronotropic agents should be discontinued when possible. A temporary cardiac pacemaker may prevent intraoperative hypotension due to bradycardia. Amiodarone may be discontinued before surgery to minimize the risk of intraoperative complications, but this decision should balance the potential for amiodarone-associated intraoperative complications against the risk of arrhythmia recurrence and the delay of surgery.

Amiodarone↗

National survey of critical-care pharmaceutical services.

The results of a national survey of critical-care pharmaceutical services are reported. A questionnaire was mailed on March 8, 1988, to 1500 of the 6800 U.S. hospitals with more than 100 beds. The questionnaire was divided into four sections: (1) critical-care pharmaceutical services; (2) critical-care clinical pharmacy activity; (3) critical-care pharmacy standards; and (4) general information on the hospital, including pharmaceutical services provided to patients who are not critically ill. A total of 613 usable questionnaires were returned, for a response rate of 41%. Respondents from 124 hospitals reported having a critical-care satellite pharmacy. Critical-care beds served by satellite pharmacies were more likely to have unit dose drug distribution services than were critical-care beds not served by satellite pharmacies. The level of clinical and educational services provided to critical-care patients was significantly lower for intensive-care unit (ICU) pharmacists practicing in satellite pharmacies than it was for ICU pharmacists not associated with satellite pharmacies. There were no differences between satellite and nonsatellite ICU pharmacists in either the percentage of a typical day spent providing clinical services to critical-care patients or the percentage of critical-care patients receiving those services. Respondents expected their hospitals to add 301 full-time-equivalent critical-care pharmacists to their staffs during the next two years, for a 39% increase. Respondents strongly favored establishing 24-hour unit dose drug distribution and i.v. admixture services, providing inservice education to nurses and physicians, and providing written pharmacokinetic consultations.(ABSTRACT TRUNCATED AT 250 WORDS)

Critical Care↗

Variability in aminoglycoside pharmacokinetics in critically ill surgical patients.

The pharmacokinetics of the aminoglycosides were evaluated in 181 patients admitted to a surgical ICU. Pharmacokinetic parameters changed from 16% to 40% during therapy requiring multiple dosage adjustments and nearly nine drug levels per patient. Dosage adjustments resulted in peak and trough serum concentrations within the therapeutic range 71% and 74% of the time. Aminoglycoside half-life (T1/2) ranged from 1.1 to 69.3 h. Aminoglycoside volume of distribution also varied considerably with an average value of 0.36 L/kg. During therapy most patients gained weight (average 8.4 kg) which correlated with their corresponding fluid gain of 11.6 L. Pharmacokinetic parameters were variable even in patients with a normal serum creatinine. Less than 50% of these patients received the recommended daily dosages. This study suggests that the aminoglycoside volume of distribution in critically ill surgical patients differs from general hospital patients and pharmacokinetic parameters change considerably during therapy. We recommend obtaining timed serum aminoglycoside concentrations early in therapy and adjusting drug dosages as needed to maintain serum concentrations in the therapeutic range.

Adult↗

Hemodialysis of amikacin in critically ill patients.

The clearance of amikacin during hemodialysis (HD) was determined in eight critically ill patients. The dialysis period averaged 3.4 h with a blood flow of 200 ml/min. The average amikacin clearance between dialysis was 7.30 +/- 4.78 (SD) ml/min which increased to 37.5 +/- 8.01 ml/min during dialysis. The average serum amikacin concentration before dialysis fell 27% after dialysis. The fraction of drug in the body removed only from dialysis averaged 21%. Although amikacin was cleared more effectively during HD compared to the interdialysis period, the small amount of drug removed suggests that routine supplemental dosing of amikacin after HD may not be necessary.

Adult↗

Pharmacoeconomic impact of critically ill surgical patients.

Financial information on 131 patients and drug-related information on 176 patients admitted to a surgical intensive care unit (ICU) were prospectively collected. The average stay was nearly five days and patients received 8.6 drugs per day for a total average exposure of 12.2 different drugs. Antibiotics and analgesics were used in over 90 percent of patients. The patients' diagnoses fit into 53 different diagnosis-related groups (DRG). Hospital costs were significantly greater than DRG payment for an average revenue loss of $17,803 per patient. Patients with a primary diagnosis of sepsis had the largest revenue loss, averaging $54,738. One hundred patients were revenue losers. Total hospital stay was statistically longer than DRG-projected length of stay. Pharmacy charges averaged 13.6 percent of total hospital charges. Patients receiving systemic antifungals, triple antibiotics, catecholamines, and total parenteral nutrition had high hospital and pharmacy costs. This study suggests that ICU patients are costly to hospitals and that drug use is expensive. We suggest that increased pharmacy involvement in the care of ICU patients may help curtail escalating drug costs in these patients.

Critical Care↗

Comparison of visual and turbidimetric methods for determining short-term compatibility of intravenous critical-care drugs.

Visual and turbidimetric methods for determining the short-term compatibility of critical-care i.v. drugs were compared. In phase 1, serial dilutions of calcium chloride and magnesium sulfate were examined visually and turbidimetrically to test the sensitivity of the spectrophotometric method used. In phase 2, i.v. solutions of dobutamine, dopamine, lidocaine, nitroglycerin, and nitroprusside were prepared and studied in all possible combinations of two, three, four and five drugs, for a total of 26 different combinations. In phase 3, 45 two-drug combinations previously reported as physically incompatible were studied. Visual inspection was conducted against a dark and a light background; changes were graded as slight, moderate, or gross. Absorbance was determined at 650 nm; an absorbance value of greater than 0.010 was considered to be evidence of turbidity. Visual, turbidimetric, and pH measurements were done at zero, one, and three hours after mixing. Samples of the calcium chloride-magnesium sulfate mixture that were graded visually as having a slight precipitate had absorbance readings less than 0.010. No physical evidence of incompatibility was observed by either method for dobutamine, dopamine, lidocaine, nitroglycerin, and nitroprusside in any combination. In phase 3, 19 drug combinations were shown to be incompatible; however, only 6 of these (31%) had absorbance readings greater than 0.010 when the visual incompatibility was first observed. There was no physical evidence of incompatibility for several drug combinations that have been listed as incompatible in commonly used references. Turbidimetry does not appear to be as reliable a method for determining the compatibility of drugs as is visual inspection against a dark and a light background.

Chemistry, Pharmaceutical↗

Influence of cardiopulmonary bypass on nitroglycerin clearance.

The effect of cardiopulmonary bypass on the clearance of nitroglycerin (NTG) was studied in seven patients scheduled for coronary artery bypass graft surgery. Intravenous NTG was administered through nonadsorbing tubing at a starting dosage of 5-10 micrograms/min and was adjusted as needed. Blood samples were obtained from the radial artery and antecubital vein before bypass and from the arterial outlet of the oxygenator during bypass at least 30 minutes apart during a constant dosage or at least 30 minutes after a dosage change. Serum concentrations were analyzed for NTG by gas chromatography. Venous NTG concentrations were always lower than concurrent arterial concentrations, with an average arteriovenous extraction of 67.2%. Serum concentrations of NTG were generally within the range associated with a therapeutic response in congestive heart failure patients. Consistent with other reports, NTG concentrations varied widely among patients and considerable intrasubject fluctuations in drug concentrations were seen. The mean +/- SD apparent clearance of NTG before bypass of 0.044 +/- 0.02 L/kg/min increased 20% to 0.052 +/- 0.02 L/kg/min during bypass (P = .05). These results suggest that cardiopulmonary bypass increases the clearance of NTG; however, the magnitude appears to be small and only partially explains the reported increased dosage needed during cardiopulmonary bypass.

Adult↗

Effect of low-dose dopamine on the pharmacokinetics of tobramycin in dogs.

Low-dose dopamine or a placebo was given to six healthy mongrel dogs, each receiving tobramycin at 2.0 mg/kg on consecutive days in a randomized crossover fashion. Dopamine increased the total and renal clearances and elimination rate constant of tobramycin by 12.5, 20, and 25.9%, respectively, suggesting that low-dose dopamine increases the clearance of tobramycin in dogs primarily through renal mechanisms.

Animals↗

Drug use in a surgical intensive care unit.

A retrospective review of drug usage in 180 patients admitted to a surgical intensive care unit was conducted. The average stay was three days and the total and daily number of drugs averaged 7.6 and 5.6, respectively. The most common drug class used was antibiotics, with cefazolin being the most commonly used antibiotic. Other commonly used drugs include analgesics, diuretics, H2-antagonists, vasoactive drugs and inotropes, antacids, and antiarrhythmics. This study indicates that patients admitted to a surgical intensive care unit are exposed to a variety of potent drugs, often given in combination over a short time period. Although further studies are needed to delineate specific aspects of drug use and patient characteristics, this study suggests that there is a need for close monitoring of drug therapy in these patients with special attention to reduction of drug costs.

Anti-Bacterial Agents↗

Ampicillin-associated seizures.

Two patients had ampicillin-associated seizures. Although they had complex medical problems, the high serum concentrations of ampicillin at the time of seizures without their recurrence after discontinuing the antibiotic suggest that the seizures were related to the ampicillin therapy.

Adult↗

Loss of nitroglycerin to cardiopulmonary bypass apparatus.

An in vitro model of a cardiopulmonary bypass (CPB) circuit using a bubble oxygenator was developed to assess the potential of this system to extract nitroglycerin (NTG). A NTG solution (100 ng/ml) was circulated through a CPB circuit at 5 L/min for 60 min. Samples obtained for NTG analysis revealed a significant loss of drug to the circuit. By 60 min, only 18% of the initial NTG concentration was present. In a separate experiment, the bubble oxygenator was shown to be the major source of drug extraction because less than 15% of the drug concentration infused directly into the oxygenator appeared in the arterial outlet. These results indicate that patients may not receive the expected dose of NTG during CPB even if caution is taken to administer the drug through nonadsorbing iv tubing.

Biological Availability↗